A
47.26
0.40 (0.85%)
| Previous Close | 46.86 |
| Open | 47.11 |
| Volume | 45,970 |
| Avg. Volume (3M) | 3,134,875 |
| Market Cap | 6,895,391,744 |
| Price / Sales | 526.10 |
| Price / Book | 5.40 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -8,360.90% |
| Diluted EPS (TTM) | -3.00 |
| Quarterly Revenue Growth (YOY) | -55.60% |
| Total Debt/Equity (MRQ) | 0.45% |
| Current Ratio (MRQ) | 16.91 |
| Operating Cash Flow (TTM) | -355.32 M |
| Levered Free Cash Flow (TTM) | -245.73 M |
| Return on Assets (TTM) | -22.47% |
| Return on Equity (TTM) | -34.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Avidity Biosciences, Inc. | Mixed | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.17% |
| % Held by Institutions | 112.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Casdin Capital, Llc | 30 Jun 2025 | 1,775,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 87.00 (HC Wainwright & Co., 84.09%) | Buy |
| Median | 65.00 (37.54%) | |
| Low | 62.00 (Roth Capital, 31.19%) | Buy |
| 62.00 (Barclays, 31.19%) | Buy | |
| Average | 69.50 (47.06%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 44.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 22 Sep 2025 | 65.00 (37.54%) | Buy | 42.34 |
| Roth Capital | 17 Sep 2025 | 62.00 (31.19%) | Buy | 40.06 |
| B of A Securities | 15 Sep 2025 | 65.00 (37.54%) | Buy | 40.22 |
| HC Wainwright & Co. | 12 Sep 2025 | 87.00 (84.09%) | Buy | 44.74 |
| Chardan Capital | 10 Sep 2025 | 75.00 (58.70%) | Buy | 46.40 |
| 08 Aug 2025 | 75.00 (58.70%) | Buy | 46.29 | |
| Needham | 10 Sep 2025 | 65.00 (37.54%) | Buy | 46.40 |
| Barclays | 08 Aug 2025 | 62.00 (31.19%) | Buy | 46.29 |
| Wells Fargo | 08 Aug 2025 | 75.00 (58.70%) | Buy | 46.29 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MCCARTHY TERESA | - | 50.47 | -20,000 | -1,009,400 |
| Aggregate Net Quantity | -20,000 | |||
| Aggregate Net Value ($) | -1,009,400 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 50.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MCCARTHY TERESA | Officer | 15 Oct 2025 | Automatic sell (-) | 20,000 | 50.47 | 1,009,400 |
| MCCARTHY TERESA | Officer | 15 Oct 2025 | Option execute | 20,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |